CStone Pharmaceuticals (HKG:2616) agreed to give commercialization rights for its sugemalimab in ten Latin American countries to Latin American pharmaceutical company SteinCares, a Jan. 27 Hong Kong bourse filing said.

Under the commercialization agreement, SteinCares will handle the regulatory affairs and commercialization activities in Brazil, Argentina, Mexico, Chile, Colombia, Costa Rica, Panama, Peru, Guatemala, and Ecuador.

The company will receive upfront, regulatory, and commercial milestone payments, along with book revenue from the overseas partner through the supply of the said drug.